There’s a particular financial gut-punch that only UiPath employees understand. You believed in the mission, shipped the work, and accumulated UiPath RSUs – restricted stock units representing real, promised compensation in a company that was, for one glittering moment, among enterprise software’s most exciting stories. PATH briefly touched $85 in early 2021. By mid-2026, it trades near $12. Your equity statement now reads less like a path to financial independence and more like a receipt from a restaurant that charged you for food that arrived cold, late, and half the size of the picture on the menu.
This guide isn’t a sympathy card. It’s a practical, honest look at where UiPath RSUs and employee stock stand in 2026 – the business, the risks, the psychology keeping many employees stuck, and the steps that actually matter. We’ll cover the real numbers, the concentration risk hiding in plain sight, and what thoughtful UiPath equity compensation management actually looks like from here.
The UiPath Stock Decline: No, We’re Not Sugarcoating It
UiPath went public in April 2021 at $65 per share, briefly trading above $85 before beginning what financial journalists might call “a challenging period” and everyone else would call “an 85% collapse.” By mid-2026, PATH hovers around $12 – well below the S&P 500, which has grown meaningfully over the same period, and dramatically below the S&P 500 Technology Index, which has roughly doubled. UiPath’s own 10-K filing on the SEC’s EDGAR database includes a stock performance chart that makes this comparison impossible to miss or misread.
For UiPath RSU holders who vested shares at $40, $50, or $60 – prices that seemed reasonable in 2021–2022 – the math is genuinely painful. RSUs vest as ordinary income: you pay taxes on the full value at the moment shares land in your account, regardless of whether you sell. If you vested at $50 and held, you paid income taxes on $50 per share in compensation. Today that same share is worth $12.
Those aren’t paper losses. They’re behavioral finance traps with real cash consequences, and they deserve to be named clearly.
Is the UiPath Business Actually Broken? (Spoiler: It’s Complicated)
Purely doom-scrolling the stock chart can mislead you. The underlying UiPath business has improved meaningfully, even if the market hasn’t gotten around to noticing.
For fiscal year 2026 (ended January 31, 2026), the company’s financials tell a story of real operational progress:
- Revenue: $1.61 billion, up 13% year over year
- Annual Recurring Revenue (ARR): $1.85 billion, up 11%
- Gross margin: 83% – exceptional by any enterprise software standard
- Operating income: $57 million, a dramatic swing from a $163 million operating loss the prior year
- Cash and marketable securities: $1.69 billion on the balance sheet
That’s not a burning building. UiPath generated $371 million in cash from operations in FY2026. The balance sheet has real substance, and the company is no longer burning investor capital to keep the lights on.
But “not a burning building” isn’t the same as “a great place to concentrate your savings.” The risks disclosed in the company’s 10-K are substantial – and every UiPath employee with meaningful equity exposure should understand them.
UiPath Equity Risks Every Employee Should Know
Single-platform dependency. Every dollar of UiPath revenue flows through the UiPath Platform. That’s either discipline or fragility – depending entirely on whether the platform keeps pace with customer demands, particularly around AI and agentic automation. There’s no fallback revenue stream.
Competition that didn’t exist five years ago. Microsoft, ServiceNow, Salesforce, and a growing wave of AI-native startups are all chasing the same enterprise automation budgets. The generative AI wave has simultaneously boosted demand for automation broadly and undercut demand for a dedicated automation layer – because competing platforms now build the capability natively. The 10-K explicitly acknowledges that “the speed of technological development may prove disruptive” if innovation pace falters.
Customer growth has effectively stalled. UiPath served approximately 10,747 customers as of January 2026 – nearly identical to the 10,753 it had a year earlier. Net revenue retention dropped from 110% to 107%. Existing accounts are expanding. New customers, however, aren’t arriving in meaningful numbers.
CEO Daniel Dines controls 85% of voting power through a dual-class share structure weighted heavily toward Class B shares. If you hold PATH stock as a UiPath employee, you own Class A shares – minority shares that carry virtually no meaningful governance rights.
Active litigation and regulatory exposure. UiPath is defending multiple securities class action lawsuits related to statements made in 2021–2022, one of which remains in active appeal. Active tax audits are underway in Romania and India, with a potential $48.7 million GST exposure in India still unresolved. These aren’t hypothetical tail risks – they’re live disputes requiring management attention and cash reserves.
What Your UiPath RSU Vesting Actually Means for Your Finances
Let’s get concrete. If you’re a current or former UiPath employee, your equity picture likely falls into one of these categories:
Unvested UiPath RSUs represent future compensation whose realized value depends entirely on where PATH trades when each tranche vests. Grants made at current prices aren’t underwater. Grants from 2021–2022 at $40–$60 per share, however, vested – when they vested at all – at a small fraction of the promised value.
Vested shares you’re holding represent a concentrated position in one company that also writes your paycheck. Concentration risk of this kind – where both your income and your investment portfolio are exposed to the same underlying risk factors – is widely considered problematic from a portfolio management standpoint. Unless you have a specific, well-reasoned thesis for PATH appreciation, the math makes a large concentrated position difficult to defend.
ESPP participation carries a built-in 15% discount (shares are purchased at 85% of the lower of the offering period’s beginning- or end-price). That discount is a genuine margin of safety. Selling ESPP shares promptly after purchase is generally the financially prudent choice for most employees. Accumulating them long-term is a different, and riskier, calculation.
The Psychological Trap Keeping UiPath Employees Stuck
This is where the conversation gets uncomfortable – because it isn’t only about numbers.
Employees at companies whose stock has declined sharply tend to anchor to a historical price: the IPO price, the original grant price, some peak the stock touched before the slide. “When PATH gets back to $40, I’ll sell.” That anchor isn’t a financial reality. It’s a cognitive one – a well-documented behavioral pattern called anchoring bias that locks people into positions long past the point of rational justification.
Ask yourself the honest question: not “Will UiPath stock recover to $65?” but “Given everything I know about this company today, if I didn’t already hold these shares, would I willingly invest my own savings in PATH at $12?”
Answering that cleanly – stripped of loyalty, of sunk-cost thinking, of the memory of what the grant price used to be – is the beginning of a genuinely informed decision.
UiPath Employee Stock: Practical Steps Worth Taking Now
You don’t need to make one dramatic, all-or-nothing call. In fact, you probably shouldn’t. Thoughtful UiPath stock management looks more like a series of deliberate moves than a single decisive moment.
Step 1: Map Your Total UiPath Equity Exposure
Before anything else, add it all up: vested shares, unvested RSU tranches with vesting dates, ESPP shares, any options still in play. Understand exactly how much of your net worth is exposed to PATH. Many employees are genuinely surprised by how large that number is once it’s all on paper. That surprise is itself useful information.
Step 2: Understand the Tax Implications of Your UiPath RSUs Vesting
RSUs vest as ordinary income – taxable the moment shares are received, at the share price on the vesting date. Subsequent sales generate either capital gains or capital losses, depending on price movement after vesting. If you’re holding shares below your tax basis (the price at which ordinary income tax was assessed), a sale generates a capital loss you may be able to use. Bringing a CPA into the conversation before making any large sales is strongly recommended.
Step 3: Consider a Systematic Selling Plan for PATH Stock
Rather than deferring the decision until “the right moment” (a moment that tends never quite to arrive), some employees use a structured, pre-scheduled selling plan to reduce concentration over time. A Rule 10b5-1 plan – the same mechanism UiPath’s own executives use to sell shares – allows pre-authorized sales that take emotional decision-making out of the equation. For significant holdings, this is worth discussing with a financial advisor.
Step 4: Benchmark Your Compensation Before Staying or Leaving
If you’re weighing whether to remain at UiPath or evaluate competing offers, Levels.fyi provides real-world compensation benchmarks across roles and companies. Value any equity component in an offer conservatively – based on realistic growth assumptions and current market conditions, not a hoped-for recovery price. Blind can add useful context on internal sentiment, too.
Should You Hold or Sell Your UiPath Equity? The Honest Answer
Nobody can responsibly predict PATH’s trajectory – and anyone who claims otherwise is either selling something or remarkably overconfident (possibly both).
What’s knowable: UiPath has real assets. $1.7 billion in cash, 83% gross margins, a recognized brand in enterprise automation, a growing agentic AI product roadmap, and a large installed base of enterprise customers. These are not nothing. A company with that kind of balance sheet and those margins isn’t disappearing quietly.
What’s also knowable: the competitive threats are structural, revenue growth is solid but unremarkable, the customer base has plateaued, and the stock has already lost more than 80% of its value from peak. Recovering to prior valuation levels would require a dramatic change in growth trajectory and investor sentiment – neither of which is guaranteed, or even clearly on the horizon.
The UiPath employees who tend to fare best with company equity aren’t usually the ones who guessed the stock direction correctly. They’re the ones who took concentration risk seriously, made deliberate and informed decisions, and resisted conflating loyalty to their employer with an obligation to hold its stock.
Bottom Line for UiPath RSU Holders
Your UiPath RSUs represent real compensation – work you genuinely did, even when today’s stock price makes that feel abstract. PATH may recover. Competitive dynamics may shift. The agentic AI buildout may prove to be exactly the growth catalyst that re-rates the stock. All of that is possible.
But making financial decisions based on what might happen – anchored to the price you remember from 2021 – is how concentration risk quietly becomes concentration damage.
Get a complete picture of your UiPath RSUs and equity compensation exposure. Understand the tax landscape before you sell or hold. Think seriously about diversification – not as pessimism, but as the rational response to holding a concentrated position in a volatile, competitive market where you also collect a paycheck.
And if you’re still anchored to $65? Give yourself permission to let it go. The stock price from 2021 isn’t coming to rescue you. A clear-eyed plan just might.
Schedule a free consultation with Fortrove Partners →
This article draws on publicly available information, including UiPath’s Form 10-K for the fiscal year ended January 31, 2026, compensation benchmarking data from Levels.fyi, and employee sentiment data from Blind. It is for informational purposes only and does not constitute personalized financial, tax, or legal advice. Your situation depends on your specific tax circumstances, overall financial picture, risk tolerance, and time horizon. Before making decisions about your equity, consult a CERTIFIED FINANCIAL PLANNER® professional and, where tax issues are involved, a CPA or tax attorney.